• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝肺综合征作为肝硬化的首发表现

Hepatopulmonary Syndrome as First Presentation of Liver Cirrhosis.

作者信息

Shrikant Sundari, Jain Anshul

机构信息

Director, Department of Internal Medicine, Accord Superspeciality Hospital, Faridabad, Haryana, India, Corresponding Author, Orcid: https://orcid.org/0009-0003-3017-2372.

Post Graduate 3rd Year, Department of Internal Medicine, Marengo Asia Hospitals, Faridabad, Haryana, India.

出版信息

J Assoc Physicians India. 2025 Jul;73(7S):47-49. doi: 10.59556/japi.73.0980.

DOI:10.59556/japi.73.0980
PMID:40836752
Abstract

A 46-year-old male nonsmoker presented to the outpatient department (OPD) with a history of progressively increasing breathlessness and central cyanosis since 1 month. He had a history of surgery for craniopharyngioma 6 years back and was on hormone replacement therapy. On evaluation, no cardiopulmonary cause was found for cyanosis. Patient was detected to have cirrhosis, possibly due to nonalcoholic fatty liver disease (NAFLD), and hepatopulmonary syndrome (HPS) was suspected as the cause for dyspnea and cyanosis, which was confirmed on workup. HPS as the first presentation of undiagnosed cirrhosis is relatively rare, although there are some case reports in the literature.

摘要

一名46岁不吸烟男性因自1个月以来进行性加重的呼吸困难和中央性发绀就诊于门诊。他6年前有颅咽管瘤手术史,目前正在接受激素替代治疗。经评估,未发现导致发绀的心肺病因。患者被检测出患有肝硬化,可能是由于非酒精性脂肪性肝病(NAFLD),并怀疑肝肺综合征(HPS)是呼吸困难和发绀的原因,检查后得以证实。HPS作为未确诊肝硬化的首发表现相对罕见,尽管文献中有一些病例报告。

相似文献

1
Hepatopulmonary Syndrome as First Presentation of Liver Cirrhosis.肝肺综合征作为肝硬化的首发表现
J Assoc Physicians India. 2025 Jul;73(7S):47-49. doi: 10.59556/japi.73.0980.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Vitamin D supplementation for chronic liver diseases in adults.成人慢性肝病的维生素D补充治疗
Cochrane Database Syst Rev. 2017 Nov 3;11(11):CD011564. doi: 10.1002/14651858.CD011564.pub2.
4
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.用于非酒精性脂肪性肝病和非酒精性脂肪性肝炎的他汀类药物。
Cochrane Database Syst Rev. 2013 Dec 27;2013(12):CD008623. doi: 10.1002/14651858.CD008623.pub2.
5
Decompensated Cirrhosis with Hepatopulmonary Syndrome in a Patient with Interrupted Treatment for Hypopituitarism.一名垂体功能减退症中断治疗患者出现失代偿性肝硬化合并肝肺综合征。
Intern Med. 2025 Aug 1;64(15):2307-2311. doi: 10.2169/internalmedicine.4753-24. Epub 2025 Jan 3.
6
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
7
The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression.非酒精性肝病患者小肠细菌过度生长的患病率:NAFLD、NASH、纤维化、肝硬化-系统评价、荟萃分析和荟萃回归。
Nutrients. 2022 Dec 9;14(24):5261. doi: 10.3390/nu14245261.
8
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.疑似酒精性肝病患者肝纤维化无创诊断评估工具的系统评价和经济评估。
Health Technol Assess. 2012;16(4):1-174. doi: 10.3310/hta16040.
9
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.非酒精性脂肪性肝病的营养补充:一项网状Meta分析。
Cochrane Database Syst Rev. 2021 Jul 19;7(7):CD013157. doi: 10.1002/14651858.CD013157.pub2.
10
Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease.超声检查在酒精性肝病患者中对酒精性肝硬化的诊断作用
Cochrane Database Syst Rev. 2016 Mar 2;3(3):CD011602. doi: 10.1002/14651858.CD011602.pub2.